AZ signs cancer development deal
pharmafile | September 13, 2010 | News story | Research and Development | AstraZeneca, CRT, Cancer Research UK
AstraZeneca has agreed a deal with charity Cancer Research UK to develop a first-in-class cancer treatment.
AZD-3965 targets the monocarboxylate transporter 1 (MCT1), which plays an essential role in cell metabolism. Blocking this transporter limits the ability of cancer cells to generate energy, and decreases their ability to survive.
The drug is ready to be taken into early phase clinical trials and is the sixth treatment to enter Cancer Research UK’s Clinical Development Partnerships (CDP) scheme.
CDP is a joint initiative between Cancer Research UK’s Drug Development Office and its spin-off development arm, Cancer Research Technology. The initiative aims to progress promising cancer drugs which pharma companies do not have the resources to move through early phase clinical trials.
The deal with AstraZeneca will enable the charity’s Drug Development Office to carry out early clinical trials of the compound to see if it can benefit cancer patients.
Dr Ian Walker, licensing manager for clinical partnerships at Cancer Research Technology, said: “It is fantastic to see a drug from our CDP programme progressing toward a clinical trial to be tested as a potential new treatment for cancer patients.
“This clinical trial simply would not have been possible without the CDP initiative, and it demonstrates how Cancer Research UK and Cancer Research Technology can work with industry to develop anti-cancer drugs that would otherwise remain on companies’ shelves. We will continue to work to set in place future similar agreements with industry with the aim of licensing more drugs to provide new treatments for patients.”
Les Hughes, global vice president of cancer research at AstraZeneca, said: “AstraZeneca is committed to the discovery and development of new, targeted anti-cancer therapies to improve the lives of cancer patients but if we are going to be successful in delivering new treatments for cancer patients, it will be important for charities, academics and industry to work collaboratively.
“Working with CRT will enable a compound with a very exciting mechanism to be evaluated in patients using Cancer Research UK’s extensive clinical network. We look forward to this collaboration adding a new dimension to AstraZeneca’s pipeline which contains a number of promising candidates already in development.”
Cancer Research UK will fund the phase I/IIa clinical trial of up to 60 patients to start in 2011. The trial will be managed by its Drug Development Office. The lead clinical trial centre will be Newcastle’s Cancer Research UK Experimental Cancer Medicine Centre Network, led by Professor Ruth Plummer.
The deal allows AstraZeneca to decide if it wishes to develop the drug further based on the results at the end of the phase I/IIa trial. If it chooses not to, the rights will be given to Cancer Research Technology to secure an alternative partner and ensure the drug has every chance of reaching patients. In either case, the charity will receive a share of any future revenues generated by the drug.
Professor Ruth Plummer, study lead at the Newcastle Experimental Cancer Medicine Centre, said: “It is incredibly exciting to have the opportunity to run a trial of a completely new type of potential drug to treat patients across a range of different cancers.
“We hope to recruit the first patient soon – and it is thanks to the generosity and time of these patients that it is possible to develop new treatments to potentially treat thousands of patients in the future.”
Dr Nigel Blackburn, director of drug development at Cancer Research UK’s Drug Development Office, said: “One of Cancer Research UK’s key aims is to boost the number of new treatments for cancer patients.
“Our strong links with industry have enabled us to make great progress by launching this clinical trial of a promising compound that without this partnership may have remained on a shelf gathering dust.”
Andrew McConaghie
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
